Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Denali Therapeutics Inc. (DNLI) [MarketWatch]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: MarketWatch
January 14, 2022 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / January 14, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Denali Therapeutics Inc. ("Denali" or the "Company") (NASDAQ:DNLI). Investors who purchased Denali securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/dnli Image: https://www.accesswire.com/users/newswire/images/672396/Bron.png The investigation concerns whether Denali and certain of its officers and/or directors have violated federal securities laws. On January 13, 2022, Denali issued a press release disclosing that on January 12, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) that the DNL919 (ATV:TREM2) Investigational New Drug (IND) application has been placed on clinical hold." Denali further advised that "[t]he FDA indicated they will provide an official
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- BioHive Announces BioHive Live [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at UBS Group AG from $70.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesPR Newswire
- Gain Therapeutics gets new chief medical officer [Seeking Alpha]Seeking Alpha
- Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
DNLI
Earnings
- 2/27/24 - Miss
DNLI
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form DEF
- DNLI's page on the SEC website